For the year ending 2025-12-31, NAMSW made $22,503,000 in revenue. -$203,493,000 in net income. Net profit margin of -904.29%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenue | 22,503,000 | |||
| Research and development expenses | 141,832,000 | |||
| Selling, general and administrative expenses | 106,354,000 | |||
| Total operating expenses | 248,186,000 | |||
| Operating loss | -225,683,000 | |||
| Interest income | 27,592,000 | |||
| Fair value change - earnout | -3,992,000 | |||
| Fair value change - warrants | 22,775,000 | |||
| Foreign exchange gains/(losses) | 13,055,000 | |||
| Loss before tax | -203,819,000 | |||
| Loss for the year | -203,819,000 | |||
| Unrealized gain on available-for-sale securities, net of tax | 326,000 | |||
| Total comprehensive loss for the year, net of tax | -203,493,000 | |||
| Basic | -1.72 | |||
| Diluted | -1.72 | |||
| Weighted average ordinary shares outstanding, basic | 118,424,231 | |||
| Weighted average ordinary shares outstanding, diluted | 118,424,231 | |||
NewAmsterdam Pharma Co N.V. (NAMSW)
NewAmsterdam Pharma Co N.V. (NAMSW)